Table I.

Demographic and baseline characteristics of patients with SARS-CoV-2 infection and uninfected controls

Parameters Characteristics	Study participants
	Asymptomatic	Mild symptomatic		Moderate+severe		Recovered	Uninfected controls
Study population (n)	53	36		30		40	56
Male	31	24		19		23	34
Female	22	12		11		17	22
Sex ratio (male: female)	1.4	2		1.7		1.35	1.54
Age (yr), median (range)	32 (12-79)	38 (15-75)		51 (29-74)		38 (18-70)	27 (18-47)
Parameters Signs and symptoms	NA	Positive cases	95% CI (range)	Positive cases	95% CI (range)	NA	NA
Fever (97.1-101 F)		21	58.33 (42-74)	28	93 (84-100)
Cough		22	61.11 (45-77)	22	73 (57-89)
Sore throat		13	36.11 (20-51)	10	33 (16-50)
Breathing difficulty		7	19.44 (6-32)	28	93 (84-100)
Body ache		6	16.67 (4-28	22	73 (57-89)
Headache		1	2.78 (0-8)	12	4 (22-57)
Diarrhoea		1	2.78 (0-8)	4	13 (1.1-25)
Nasal discharge		9	25 (10-39)	0	0
Nausea vomiting		0	0	8	26 (10-42)
Dysuria		0	0	2	6 (0-15)
Abdominal pain		0	0	3	10 (0-20)
Anosmia		0	0	4	13 (1-25)
Loss of smell and taste		0	0	9	30 (13-43)
Post onset days of illness, median (range)	NA	7 (0-17)		6 (1-15)		45-60*	NA
Chronic medical illness/comorbidities	NA	NA		Positive/total number of cases	95% CI (range)	NA	NA
Condition tuberculosis				1	3 (0-9)
Diabetes				12	40 (22-57)
Hypertension				14	46 (28-64)
Heart disease				1	3 (0-9)
Cancer				0	0
COPD				0	0
Liver failure				0	0
Dialysis				0	0
HIV				0	0
Kidney disease				0	0
Sickle cell disease or thalassaemia				0	0
Sepsis				6	20 (5-34)
ARDS				7	23 (8-38)
ARDS with AKI				1	3.33 (0-9)

^* recovered from mild symptomatic infection; ^# not applicable. ARDS: acute respiratory distress syndrome; AKI: acute kidney injury; NA: not available; COPD: Chronic obstructive pulmonary disease: Human Immunodeficiency Virus